This message contains images. If you don't see images, click here to view. Click here to advertise in this news brief.

Mobile version   RSS   Subscribe   Unsubscribe   Archive   Media Kit Feb. 15, 2012 Home   About The ATA   Join   Fellows' Corner
		Treatment for hypothyroidism during pregnancy may not improve cognitive function in children Endocrine Today    Share    Children of women who were treated for hypothyroidism during pregnancy had similar IQ results at age 3 years as children of women who were not treated, according to recent results. The trial was conducted to build on previous evidence that children born to women with low thyroid hormone levels have decreased cognitive function. More Use of radioiodine ablation for thyroid cancer has increased and varies inexplicably among hospitals Clinical Thyroidology    Share    Radioactive iodine-131 has been administered after thyroidectomy for differentiated thyroid cancer for half a century to eliminate residual thyroid tissue and possible metastatic disease. After initial surgery, the indications for radioiodine ablation have not been rigidly defined, leading to considerable variability in its use. The purpose of this study was to determine possible change in practice patterns and the degree to which hospitals in the United States vary in their use of radioactive iodine ablation and the factors that contribute to these variations. More Advertisement Hyperparathyroidism charting in EMR can be easy With the right tools and workflow, charting an initial consultation for Hyperparathyroidism can be very easy and quick. You can also setup and manage reminders for yearly calcium levels automatically. Click here to see the video. MORE Determining which thyroid cancer patients are at low risk for cancer recurrence Clinical Thyroidology for Patients    Share    Patients with thyroid cancer initially undergo surgery to remove the thyroid. This may be followed by radioactive iodine therapy. Because only a relatively few patients will die of thyroid cancer, the main risk is for cancer recurrence. Identification of patients at high risk for cancer recurrence would allow more aggressive follow up and treatment. Identification of those patients at low risk would decrease the need for close follow up. The aim of this study was to find out how well testing of patients with thyroid cancer at 8 to 12 months following initial surgery could identify high and low risk patients for cancer recurrence. More 2 commonly available 'third generation' assays for antibodies to the TSH receptor are similar in sensitivity and specificity, but differ in their response to sera containing TSHR-blocking IgGs Clinical Thyroidology    Share    How antibodies activate the thyroid-stimulating hormone receptor remains controversial, but it is clear that immunoglobulins that bind to the TSHR and that stimulate adenylate cyclase can be found in the serum of most patients with untreated Graves' disease. This article compared two widely available "third generation" assays for measuring TSHR antibodies. The first assay measures the ability of a patient's serum to stimulate cyclic adenosine monophosphate production in cells transfected to express a synthetic mutant of the human TSHR (two authors are affiliated with the company that markets this assay). The other assay measures the ability of a patient's serum to inhibit the binding of a TSHR-stimulating antibody to an extract of porcine thyroid membranes. More
ATA Thyroid Weekly News Briefs ATA does not develop, exert any editorial or other control, or guarantee the accuracy, completeness, efficacy, or timeliness, of the materials, information, advertising or promotional activities ("Content") in this publication. Inclusion of Content in this publication does not constitute or imply endorsement, agreement, recommendation, or favoring by ATA of such information or the entities mentioned or promoted herein. Use of any Content appearing or referenced in this publication or obtained from advertisers is voluntary, and reliance on it should only be undertaken after an independent review by qualified experts. ATA is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use of, reference to, reliance on, or performance pursuant to such Content. Colby Horton, Vice President of Publishing, 469.420.2601 Download media kit Julie Bernhard, Sr. Content Editor, 469.420.2647    Contribute news This edition of the ATA Thyroid Weekly News Briefs was sent to %%emailaddr%%. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free! Recent issues Feb. 15, 2012 Feb. 8, 2012 Feb. 1, 2012 Jan. 25, 2012

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063